Table 3.
Univariate analysis and multivariate Cox regression analysis for overall survival in the Propensity score matched cohort.
| Variables | Univariate analysis | Multivariate analysis 1 | Multivariate analysis 2 | Multivariate analysis 3 | Multivariate analysis 4 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Pre-anemia | ||||||||||
| No | 1 (reference) | 1 (reference) | ||||||||
| Yes | 1.200 (1.058-1.360) | 0.005 | 1.144 (1.005-1.302) | 0.042 | ||||||
| Post-anemia | ||||||||||
| No | 1 (reference) | 1 (reference) | ||||||||
| Yes | 1.248 (1.099-1.419) | 0.001 | 1.186 (1.042-1.350) | 0.010 | ||||||
| Pre-Anemia and post-anemia | 0.003 | 0.060 | ||||||||
| Neither pre- nor post-anemia | 1 (reference) | 1 (reference) | ||||||||
| Post-anemia but not pre-anemia | 1.316 (1.059-1.634) | 0.013 | 1.228 (0.987-1.528) | 0.066 | ||||||
| Pre-anemia but not post-anemia | 1.253 (0.931-1.686) | 0.136 | 1.147 (0.847-1.553) | 0.377 | ||||||
| Both pre- and post-anemia | 1.274 (1.109-1.464) | 0.001 | 1.202 (1.043-1.385) | 0.011 | ||||||
| Pre-anemia and transfusion | 0.001 | <0.001 | ||||||||
| Not pre-anemia and not transfused | 1 (reference) | 1 (reference) | ||||||||
| Not pre-anemia but transfused | 2.144 (0.888-5.178) | 0.090 | 1.735 (0.714-4.213) | 0.224 | ||||||
| Pre-anemia but not transfused | 1.173 (1.030-1.335) | 0.016 | 1.239 (1.079-1.423) | 0.002 | ||||||
| Pre-anemia and transfused | 1.606 (1.213-2.125) | 0.001 | 1.791 (1.339-2.397) | <0.001 | ||||||
| Perioperative blood transfusion | ||||||||||
| No | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||||
| Yes | 1.516 (1.167-1.969) | 0.002 | 1.428 (1.092-1.868) | 0.009 | 1.443 (1.107-1.881) | 0.007 | 1.431 (1.094-1.871) | 0.009 | ||
| Sex | ||||||||||
| Male | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |||||
| Female | 0.833 (0.733- 0.945) | 0.005 | 0.857 (0.754-0.975) | 0.019 | 0.854 (0.751-0.971) | 0.016 | 0.851 (0.748-0.968) | 0.014 | 0.857 (0.753-0.975) | 0.019 |
| Age, years | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||
| ≤44 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |||||
| 45-54 | 1.072 (0.825-1.393) | 0.602 | 1.180 (0.906-1.538) | 0.220 | 1.179 (0.905-1.537) | 0.222 | 1.181 (0.906-1.540) | 0.217 | 1.207 (0.925-1.573) | 0.165 |
| 55-64 | 1.230 (0.968-1.561) | 0.090 | 1.315 (1.032-1.676) | 0.027 | 1.313 (1.031-1.673) | 0.027 | 1.314 (1.031-1.674) | 0.027 | 1.343 (1.053-1.712) | 0.017 |
| 65-74 | 1.504 (1.186-1.907) | 0.001 | 1.699 (1.334-2.163) | <0.001 | 1.690 (1.327-2.152) | <0.001 | 1.688 (1.325-2.149) | <0.001 | 1.773 (1.390-2.261) | <0.001 |
| ≥75 | 2.337 (1.834-2.979) | <0.001 | 3.194 (2.489-4.098) | <0.001 | 3.163 (2.465-4.059) | <0.001 | 3.156 (2.459-4.050) | <0.001 | 3.287 (2.560-4.220) | <0.001 |
| Preoperative adjuvant chemotherapy | ||||||||||
| No | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |||||
| Yes | 1.256 (1.016-1.553) | 0.035 | 1.762 (1.372-2.261) | <0.001 | 1.756 (1.368-2.254) | <0.001 | 1.744 (1.358-2.239) | <0.001 | 1.554 (1.201-2.010) | 0.001 |
| Tumor histology | 0.002 | 0.162 | 0.185 | 0.174 | 0.167 | |||||
| Adenocarcinoma | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |||||
| Mucoid adenocarcinoma | 0.976 (0.820-1.162) | 0.788 | 0.926 (0.766-1.120) | 0.430 | 0.929 (0.768-1.123) | 0.445 | 0.928 (0.767-1.122) | 0.440 | 0.927 (0.766-1.122) | 0.436 |
| Signet-ring cell carcinoma | 2.336 (1.444-3.778) | 0.001 | 1.518 (0.917-2.512) | 0.104 | 1.495 (0.903-2.475) | 0.118 | 1.506 (0.910-2.495) | 0.112 | 1.514 (0.914-2.506) | 0.107 |
| Tumor differentiation | <0.001 | 0.014 | 0.012 | 0.013 | 0.008 | |||||
| Well | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 | |||||
| Moderate | 1.888 (1.010-3.529) | 0.046 | 1.247 (0.663-2.343) | 0.494 | 1.238 (0.659-2.328) | 0.507 | 1.232 (0.655-2.316) | 0.518 | 1.206 (0.641-2.269) | 0.562 |
| Poor | 2.883 (1.533-5.423) | 0.001 | 1.570 (0.827-2.980) | 0.167 | 1.563 (0.824-2.966) | 0.172 | 1.553 (0.818-2.948) | 0.178 | 1.546 (0.814-2.936) | 0.183 |
| Unknown | 1.998 (1.032-3.866) | 0.040 | 1.501 (0.764-2.949) | 0.239 | 1.498 (0.763-2.944) | 0.241 | 1.487 (0.757-2.922) | 0.250 | 1.458 (0.741-2.867) | 0.275 |
| Vascular cancer embolus | ||||||||||
| No | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |||||
| Yes | 2.214 (1.939-2.527) | <0.001 | 1.490 (1.286-1.726) | <0.001 | 1.492 (1.288-1.729) | <0.001 | 1.489 (1.285-1.725) | <0.001 | 1.493 (1.287-1.730) | <0.001 |
| Surgical margin positive | ||||||||||
| No | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |||||
| Yes | 3.105 (2.158-4.467) | <0.001 | 1.541 (1.051-2.259) | 0.027 | 1.585 (1.083-2.322) | 0.018 | 1.554 (1.058-2.284) | 0.025 | 1.558 (1.063-2.285) | 0.023 |
| pTNM/UICC stage | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||
| 0-I | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |||||
| II | 1.185 (0.885-1.587) | 0.255 | 1.205 (0.897-1.619) | 0.215 | 1.202 (0.895-1.614) | 0.222 | 1.201 (0.894-1.613) | 0.223 | 1.257 (0.935-1.689) | 0.130 |
| III | 2.480 (1.882-3.267) | <0.001 | 1.959 (1.468-2.614) | <0.001 | 1.947 (1.459-2.599) | <0.001 | 1.950 (1.461-2.602) | <0.001 | 2.022 (1.514-2.700) | <0.001 |
| IV | 8.982 (6.608-12.209) | <0.001 | 7.069 (5.097-9.804) | <0.001 | 7.020 (5.062-9.735) | <0.001 | 7.053 (5.085-9.783) | <0.001 | 7.718 (5.549-10.735) | <0.001 |
| Unkown | 0.766 (0.365-1.607) | 0.481 | 0.523 (0.239-1.142) | 0.104 | 0.518 (0.237-1.132) | 0.099 | 0.518 (0.237-1.132) | 0.099 | 0.528 (0.242-1.154) | 0.110 |
| Infiltrating lymph nodes>12, n (%) | ||||||||||
| No | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |||||
| Yes | 0.710 (0.605-0.833) | <0.001 | 0.839 (0.707-0.997) | 0.046 | 0.836 (0.704-0.993) | 0.042 | 0.836 (0.704-0.993) | 0.041 | 0.857 (0.721-1.019) | 0.080 |
| Number of cancer nodule>1, n (%) | ||||||||||
| No | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | |||||
| Yes | 2.469 (2.288-3.066) | <0.001 | 1.469 (1.248-1.729) | <0.001 | 1.473 (1.252-1.734) | <0.001 | 1.468 (1.247-1.728) | <0.001 | 1.455 (1.236-1.713) | <0.001 |
| Amount of blood loss | ||||||||||
| <400ml | 1 (reference) | |||||||||
| ≥400ml | 1.781 (0.955-3.320) | 0.070 | ||||||||
| Reoperation within 30 days | ||||||||||
| No | 1 (reference) | |||||||||
| Yes | 1.021 (0.631-1.649) | 0.934 | ||||||||
Data shown as HR [hazard ratio] (95% CI [confidence interval]). pTNM/UICC stage, Pathologic Tumor Node Metastasis / Union for International Cancer Control stage; RBC, Red blood cell. Significance with P < 0.05.